Kantartzis Konstantinos, Fritsche Andreas, Tschritter Otto, Thamer Claus, Haap Michael, Schäfer Silke, Stumvoll Michael, Häring Hans-Ulrich, Stefan Norbert
Department of Internal Medicine, Division of Endocrinology, Metabolism, and Pathobiochemistry, University of Tübingen, Otfried-Müller-Strasse 10, D-72076 Tübingen, Germany.
Obes Res. 2005 Oct;13(10):1683-91. doi: 10.1038/oby.2005.206.
In humans, low plasma adiponectin concentrations precede a decrease in insulin sensitivity and predict type 2 diabetes independently of obesity. However, it is possible that the contribution of adiponectin to insulin sensitivity is not equally strong over the whole range of obesity.
We investigated the cross-sectional association between plasma adiponectin levels and insulin sensitivity in different ranges of body fat content [expressed as percentage of body fat (PFAT)] in a large cohort of normal glucose-tolerant subjects (n = 900). All individuals underwent an oral glucose tolerance test (OGTT), and 299 subjects additionally a euglycemic hyperinsulinemic clamp. In longitudinal analyses, the association of adiponectin at baseline with change in insulin sensitivity was investigated in a subgroup of 108 subjects.
In cross-sectional analyses, the association between plasma adiponectin and insulin sensitivity, adjusted for age, gender, and PFAT, depended on whether subjects were lean or obese [p for interaction adiponectin x PFAT = <0.001 (OGTT) and 0.002 (clamp)]. Stratified by quartiles of PFAT, adiponectin did not correlate significantly with insulin sensitivity in subjects in the lowest PFAT quartile (R2 = 0.10, p = 0.13, OGTT; and R2 = 0.10, p = 0.57, clamp), whereas the association in the upper PFAT quartile was rather strong (R2 = 0.36, p < 0.0001, OGTT; and R2 = 0.48, p = 0.003, clamp). In longitudinal analyses, plasma adiponectin at baseline preceded change in insulin sensitivity in obese (n = 54, p = 0.03) but not in lean (n = 54, p = 0.68) individuals.
These data suggest that adiponectin is especially critical in sustaining insulin sensitivity in obese subjects. Thus, interventions to reduce insulin resistance by increasing adiponectin concentrations may be effective particularly in obese, insulin-resistant individuals.
在人类中,血浆脂联素浓度降低先于胰岛素敏感性下降,且独立于肥胖可预测2型糖尿病。然而,脂联素对胰岛素敏感性的作用在整个肥胖范围内可能并不同样强大。
我们在一大群糖耐量正常的受试者(n = 900)中,研究了不同体脂含量范围[以体脂百分比(PFAT)表示]内血浆脂联素水平与胰岛素敏感性之间的横断面关联。所有个体均接受口服葡萄糖耐量试验(OGTT),另外299名受试者接受了正常血糖高胰岛素钳夹试验。在纵向分析中,在108名受试者的亚组中研究了基线脂联素与胰岛素敏感性变化之间的关联。
在横断面分析中,经年龄、性别和PFAT校正后,血浆脂联素与胰岛素敏感性之间的关联取决于受试者是瘦还是胖[脂联素×PFAT交互作用的p值 = <0.001(OGTT)和0.002(钳夹试验)]。按PFAT四分位数分层,在PFAT最低四分位数的受试者中,脂联素与胰岛素敏感性无显著相关性(R2 = 0.10,p = 0.13,OGTT;R2 = 0.10,p = 0.57,钳夹试验),而在PFAT较高四分位数中,这种关联相当强(R2 = 0.36,p < 0.0001,OGTT;R2 = 0.48,p = 0.003,钳夹试验)。在纵向分析中,基线时的血浆脂联素在肥胖个体(n = 54,p = 0.03)中先于胰岛素敏感性变化,但在瘦个体(n = 54,p = 0.68)中并非如此。
这些数据表明脂联素在维持肥胖受试者的胰岛素敏感性方面尤为关键。因此,通过增加脂联素浓度来降低胰岛素抵抗的干预措施可能对肥胖的胰岛素抵抗个体特别有效。